miR-539-5p regulates Srebf1 transcription in the skeletal muscle of diabetic mice by targeting DNA methyltransferase 3b

Devesh Kesharwani,1,2 Amit Kumar,1,2 Ashima Rizvi,1,2 and Malabika Datta1,2

1CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi 110007, India; 2Academy of Scientific and Innovative Research, CSIR-HRDC, Kamala Nehru Nagar, Ghaziabad, Uttar Pradesh 201002, India

Abstract

Aberrant DNA methylation is associated with diabetes, but the precise regulatory events that control the levels and activity of DNA methyltransferases (DNMTs) is not well understood. Here we show that miR-539-5p targets Dnmt3b and regulates its cellular levels. miR-539-5p and Dnmt3b show inverse patterns of expression in skeletal muscle of diabetic mice. By binding to the 3’ UTR of Dnmt3b, miR-539-5p downregulates its levels in C2C12 cells and in human primary skeletal muscle cells. miR-539-5p-Dnmt3b interaction regulates Srebf1 transcription by altering methylation at CpG islands within Srebf1 in C2C12 cells. Dnmt3b inhibition alone was sufficient to upregulate Srebf1 transcription. In vivo antagonism of miR-539-5p in normal mice induced hyperglycemia and hyperinsulinemia and impaired oral glucose tolerance. These mice had elevated Dnmt3b and decreased Srebf1 levels in skeletal muscle. db/db mice injected with miR-539-5p mimics showed improved circulatory glucose and cholesterol levels. Oral glucose tolerance improved together with normalization of Dnmt3b and Srebf1 levels in skeletal muscle. Our results support a critical role of miR-539-5p and Dnmt3b in aberrant skeletal muscle metabolism during diabetes by regulating Srebf1 transcription; modulating the miR-539-5p-Dnmt3b axis might have therapeutic potential for addressing altered skeletal muscle physiology during insulin resistance and type 2 diabetes.

INTRODUCTION

Type 2 diabetes is a highly complex metabolic disease marked by insulin resistance and/or impaired insulin secretion. A strong genetic association is implicated in the manifestation of diabetes, but most of these incompletely explain the high discordance among monozygotic twins and close correlations with environmental factors. Therefore, non-genetic factors, primarily epigenetic modifications, gradually gained acceptance as critical contributing causal factors of the onset and progression of diabetes. An epigenome association study has reported alterations in DNA methylation patterns to be closely linked to whole-body insulin sensitivity.

DNA methyltransferases (DNMTs) catalyze the reversible covalent transfer of a methyl group to the C-5 position of a cytosine residue in the DNA, usually present in stretches of CpG islands. In mammals, DNMTs encompass a family of five members: DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L. However, only DNMT1, DNMT3a, and DNMT3b demonstrate DNA methyl transfer activity. Although DNMT1 is involved in the replication process, DNMT3a and DNMT3b are de novo DNMTs and are implicated in establishing new DNA methylation patterns. Such patterns undergo dynamic and reversible remodeling that determines transcript levels of various genes during different cellular processes that consequently govern cell fate and function. Therefore, regulatory events that determine the levels and function of DNMTs are important for maintenance of normal cellular physiology.

As with other genes, DNMTs are also regulated at transcriptional, translational, and post-translational levels. At the transcriptional level, DNMTs are regulated by several transcription factors, such as Sp1, Sp3, p53, Rb, Foxo3a, etc. The promoters of DNMT3a and DNMT3b contain multiple binding sites for several transcription factors; Sp1 acts as transcriptional activator, and Sp3 acts as an activator or a repressor of Sp1-mediated transcription. In a colon carcinoma cell line, HCT116, p53 negatively regulates DNMT1 expression by forming a complex with Sp1. The promoters of DNMT1 and DNMT3a also harbor binding sites for E2F, and the Rb protein inhibits DNMT expression by binding with E2F and consequently promoting global hypomethylation. DNMT3b expression is negatively regulated by Foxo3a by interacting with specific binding sites on the DNMT3b promoter.

Several reports suggest that DNMTs are also regulated by post-translational modifications. Cellular levels and activities of DNMT1 and DNMT3a have been shown to be influenced by post-translational modifications like phosphorylation, methylation, and SUMOylation. Although SUMOylation of DNMT3a modifies its ability to interact with other proteins, lysine methylation of...
DNMT1 affects its stability and signals for its proteasomal degradation. The cellular activity and genome methylation patterns are determined by serine phosphorylation of DNMTs. It is believed that an interplay between the various regulatory post-translational modifications of DNMTs determines their stability and activity. The RNA binding protein HuR has been shown to post-translationally regulate DNMT3b by binding to its 3' UTR and increasing its levels in colorectal cancer cells, affecting DNMT3b-specific target DNA methylation.

In addition, microRNAs (miRNAs) have, in the recent past, been identified as major regulators of DNMTs. Particularly members of the miR-29 family have been reported to directly target DNMT3a and DNMT3b and affect global DNA methylation. miR-29b targets and downregulates Sp1, a major transcriptional regulator of DNMT1, and indirectly regulates its levels. miR-148 targets DNMT3b and DNMT1 and promotes DNA hypomethylation of methylation-sensitive genes. DNMT1 has been reported to be targeted by miR-126 and miR-152 by specific binding at the 3' UTR, resulting in silencing of crucial methylation-sensitive tumor suppressor genes.

Despite these regulatory features of DNMT modulation, not much is known about such events in skeletal muscle during diabetes. This is significant because it is known that DNMT levels and activity are increased in skeletal muscle and subsequently modify the methylome, as seen in this tissue during diabetes.

In this study, we present data to demonstrate the regulation of DNMT3b by miR-539-5p and the resulting consequences of this event for impaired skeletal muscle physiology during diabetes.

RESULTS

DNMT and miRNA expression is altered in skeletal muscle of db/db mice

Several studies have shown altered patterns of DNA methylation in skeletal muscle during diabetes. In this study, we sought to evaluate whether miRNAs might regulate the expression of DNMTs and consequently regulate DNA methylation patterns. In a previous study from our laboratory, we had shown that, compared with normal db/+ mice, there exists an altered miRNA signature in skeletal muscle of diabetic db/db mice. To interrogate whether these altered miRNAs might target DNMTs in skeletal muscle, we used online tools that predict miRNA-target-interacting sites (TargetScan, miRanda, and miRDB). Although Dnmt3b was predicted to be targeted by three downregulated miRNAs, mir-539-5p, mir-381-3p, and mir-31-5p, Dnmt3a was a potential target of mir-374, mir-455, and mir-883a-3p. None of the altered miRNAs were predicted to target Dnmt1. We therefore began this study by evaluating the status of Dnmt3a and Dnmt3b in skeletal muscle of diabetic mice. Although transcript and protein levels of Dnmt3b were significantly elevated in skeletal muscle of diabetic mice, those of Dnmt3a were unchanged. Concomitantly, compared with normal mice, DNMT activity was significantly increased in skeletal muscle of diabetic mice. Although Dnmt1 was not predicted to be targeted by any of the altered miRNAs as stated above, we desired to assess the levels of DNMT1 in skeletal muscle of normal and diabetic mice. As shown in Figure 1F, compared with normal db/+ mice, DNMT1 levels were significantly decreased in skeletal muscle of diabetic mice. Because DNMT activity is increased (Figure 1E) in skeletal muscles of diabetic db/db mice, we think this is the result of increased DNMT3b levels. Because DNMT3b levels were increased and also predicted to be targeted by the downregulated miRNAs, we probed the status of the miRNAs that were predicted to target Dnmt3b and therefore, might be responsible for the observed changes in DNMT3b levels (Figures 1B and 1D). TargetScan, miRDB, and miRanda revealed Dnmt3b to be targeted by the downregulated miRNAs mir-539-5p, mir-381-3p, and mir-31-5p. The expression of these three miRNAs was validated in skeletal muscle of db/db mice. As in the microarray profiling in a previous study, compared with normal mice, the levels of all the three miRNAs were significantly downregulated in the skeletal muscle during diabetes (Figures 1G–1I). Such inverse patterns of expression between Dnmt3b and these three miRNAs indicate that Dnmt3b levels might be regulated by these miRNAs during diabetes.

miR-539-5p targets Dnmt3b by binding to its 3' UTR

To validate the above, C2C12 cells were transfected with varied doses of miRNA mimics (1–50 nM) corresponding to miR-539-5p, miR-381-3p, and miR-31-5p, and the levels of DNMT3b were evaluated by Western blot analysis. There was a significant dose-dependent decrease in expression of DNMT3b in the presence of miR-539-5p (Figure 2A). However, there was no significant change in expression of DNMT3b with overexpression of miR-381-3p or miR-31-5p in C2C12 cells (Figure 2A). The miR-539-5p mimic-mediated (50 nM) decrease in DNMT3b levels was significantly prevented in the presence of the miR-539-5p inhibitor (Figures 2B and 2C) at the transcript and protein level, suggesting a specific effect of miR-539-5p on DNMT3b. Overexpression of miR-539-5p mimics at a dose of 50 nM caused an almost 500-fold increase over its endogenous levels (~60,000 copies/cell) (data not shown). To validate direct binding of miR-539-5p on Dnmt3b, we generated luciferase reporter constructs of the wild-type 3' UTR (wild type [WT]) of Dnmt3b harboring the miR-539-5p binding site (Figure 2D) and also a mutated construct (MT) with a swap of 4 nt within the seed region of miR-539-5p binding site (Figure 2D). C2C12 cells were co-transfected with the WT or the MT 3' UTR reporter plasmid along with the miR-539-5p mimic with or without the miR-539-5p inhibitor. There was a significant decrease in the luciferase activity of the WT construct in the presence of miR-539-5p, and this was significantly prevented in the presence of miR-539-5p inhibitor (Figures 2B and 2C) at the transcript and protein level, suggesting a specific effect of miR-539-5p on DNMT3b. Overexpression of miR-539-5p mimics at a dose of 50 nM caused an almost 500-fold increase over its endogenous levels (~60,000 copies/cell) (data not shown). To validate direct binding of miR-539-5p on Dnmt3b, we generated luciferase reporter constructs of the wild-type 3' UTR (wild type [WT]) of Dnmt3b harboring the miR-539-5p binding site (Figure 2D) and also a mutated construct (MT) with a swap of 4 nt within the seed region of miR-539-5p binding site (Figure 2D). C2C12 cells were co-transfected with the WT or the MT 3' UTR reporter plasmid along with the miR-539-5p mimic with or without the miR-539-5p inhibitor. There was a significant decrease in the luciferase activity of the WT construct in the presence of miR-539-5p, and this was significantly prevented in the presence of miR-539-5p inhibitor (Figures 2B and 2C).
Dnmt3b transcript in the streptavidin pull-down complex (Figure 2F).

All of this suggests that miR-539-5p targets Dnmt3b and inhibits its expression by binding to its 3’ UTR.

Such a miR-539-5p and Dnmt3b interaction was validated in primary human skeletal muscle cells, where miR-539-5p significantly inhibited expression of DNM3b, and this inhibition was prevented in the presence of a miR-539-5p inhibitor (Figure 2G). The inverse pattern of expression between miR-539-5p and Dnmt3b in db/db mice (Figure 1) was validated in a high-fat diet (HFD) model of obesity and diabetes. Compared with chow-diet fed mice, although expression of miR-539-5p was significantly downregulated (Figure 2H), Dnmt3b transcript levels were significantly upregulated (Figure 2I) in skeletal muscle of HFD-fed mice. This suggests that miR-539-5p levels are downregulated in skeletal muscle during obesity and diabetes and that, by targeting Dnmt3b, this miRNA might be responsible for the deregulated skeletal muscle physiology in these states.

Figure 1. Expression of DNMTs and miRNAs is altered in skeletal muscle of db/db mice

(A and B) Total RNA was isolated from the skeletal muscles of normal (db/) and diabetic (db/db) mice, and 1 µg RNA was reverse transcribed and subjected to qRT-PCR to assess the transcript levels of Dnmt3a (A) and Dnmt3b (B). 18S rRNA was used as the loading control. (C and D) Skeletal muscle of normal (db/) and diabetic (db/db) mice was lysed as described under “Materials and methods;” 40-µg lysates were run on SDS-PAGE, and the levels of DNM3a (C) and DNM3b (D) were evaluated by western blot analysis. HSC70 was used as a loading control. Densitometric analyses of the expression are shown below. (E) Skeletal muscle of normal (db/) and diabetic (db/db) mice was lysed as described under “Materials and methods;” and 20-µg lysates were used to measure DNMT activity. (F) DNMT1 protein levels were assessed in skeletal muscle of db/+ and db/db mice by western blot analyses, where 40 µg protein was resolved on SDS-PAGE and probed with a DNMT1 antibody. HSC70 was used as the loading control. Densitometric analyses of the expression are shown below. (G-I) Total RNA was isolated from skeletal muscle of normal (db/) and diabetic (db/db) mice, and 1 µg RNA was reverse transcribed and subjected to qRT-PCR for expression of miR-539-5p (G), miR-381-3p (H), and miR-31-5p (I). All experiments were performed in at least four animals in each group, and values are reported as means ± SEM. *p < 0.05, **p < 0.01.

miR-539-5p targets Dnmt3b and regulates Srebf1 levels in C2C12 cells

Because DNMT activity and DNMT3b levels are upregulated in skeletal muscle during diabetes, and this would likely hypermethyrate and promote gene silencing, to assess the cellular relevance, we looked for consequent effects on a set of downregulated genes in skeletal muscle of db/db mice taken from a recent study from our laboratory.27 Pathway enrichment analysis (using DAVID Pathway Analysis 6.8) of the downregulated genes revealed pathways of AMPK and insulin signaling to be significantly overrepresented.27 Both of these pathways are critical in skeletal muscle metabolism, and three common
Figure 2. miR-539-5p inhibits Dnmt3b levels by binding to its 3’ UTR

(A) Differentiated C2C12 cells were transfected with the scramble (Scr) or mimics of miR-539-5p, miR-381-3p, or miR-31-5p (1–50 nM). Upon termination of incubation at 48 h, cells were lysed, and 40 μg protein was subjected to western blot analysis using a Dnmt3b antibody. HSC70 was used as a loading control. Densitometric analyses of the blots are shown below. (B) Differentiated C2C12 cells were transfected with the Scr or the miR-539-5p mimic with or without its inhibitor. After 48 h, transcript levels of Dnmt3b were quantified by qRT-PCR. 18S rRNA was taken as the loading control. (C) Cells incubated as in (B) were lysed, and lysates (40 μg) were assessed for Dnmt3b protein levels by western blot analysis using a Dnmt3b antibody. HSC70 was used as a loading control. Densitometric analysis of the blots is shown below. (D) Depiction of the miR-539-5p binding site in the 3’ UTR of Dnmt3b and the mutations (red) incorporated in the miRNA binding site of the Dnmt3b 3’ UTR (MT) as described under “Materials and methods.” (E) C2C12 cells were transfected with wild-type (WT) or mutated (MT) 3’ UTR luciferase constructs of Dnmt3b together with the Scr or the miR-539-5p mimic with or without its inhibitor. After 48 h of incubation, cells were harvested, and luciferase activity was measured as described under “Materials and methods.” Renilla luciferase activity was normalized to firefly luciferase activity. (F) C2C12 cells were transfected with biotin-labeled Scr or biotin-labeled miR-539-5p mimic (50 nM), and after 48 h, cells were harvested, lysed, and pulled down using streptavidin-linked Dynabeads. Enrichment of Dnmt3b mRNA in biotin-labeled Scr- or miR-539-5p mimic-transfected cells was quantified by real-time PCR using Dnmt3b-specific primers. (G) Primary human skeletal muscle cells were transfected with the Scr or the miR-539-5p mimic with or without its inhibitor. Upon termination of incubation (48 h), Dnmt3b expression was assessed by western blot analysis using a Dnmt3b antibody. HSC70 was used as a loading control. Densitometric analysis of the same is given alongside the blot. All experiments were performed in at least 3 sets for each group. (H and I) 18S rRNA and Sno234, respectively, were used as normalization controls. Values are means ± SEM. *p < 0.05, **p < 0.01.

genomes, Prkab2, Srebf1, and Irs1 (Figure 3A), from these pathways are significantly downregulated in skeletal muscles of db/db mice, as revealed by RNA sequencing. The expression of these genes in skeletal muscles of db/+ and db/db mice was validated by qRT-PCR, and, as in the RNA sequencing data, these genes were significantly downregulated in db/db mice skeletal muscle (Figure 3B). We hypothesized that this downregulation might be mediated by increased Dnmt3b levels, and to investigate this, we examined the presence of CpG islands within these genes. All three genes, Prkab2, Srebf1, and Irs1, harbored varied lengths of CpG islands across their gene lengths (Figure 3C), indicating a possibility of them being regulated by DNA methylation.

For validation, C2C12 cells were transfected with the scramble or miR-539-5p mimic with or without its inhibitor for 48 h. There
was no change in the transcript levels of Prkab2 or Irs1 in the presence of miR-539-5p. Interestingly, miR-539-5p caused a significant increase in the transcript levels of Srebf1, which was prevented in the presence of its inhibitor (Figure 4A), suggesting that, because Srebf1 harbors CpG islands, presumably by inhibiting DNMT3b levels, miR-539-5p decreases methylation of Srebf1 and increases its levels. To validate this, C2C12 cells were transfected with the scramble or the miR-539-5p mimic, and the methylation status of Srebf1 was evaluated by methylated DNA immunoprecipitation (MeDIP). Using the UCSC genome browser, two CpG-rich regions were captured within Srebf1: site 1 spanning across the promoter and exon 1 and site 2 within intron 1 (Figure 4B). Compared with scramble-transfected cells, there was a significant decrease in methylation at site 1, but there was no significant change at site 2 (Figure 4C), suggesting a role of this miRNA in regulating Srebf1 methylation by targeting Dnmt3b and, consequently, regulating its levels. This methylation status was also validated in vivo in normal (db/+), diabetic (db/db), and normal and diabetic (db/+ db/db) mouse skeletal muscle, and, as shown in Figure 4D, there was significant hypermethylation of Srebf1 in db/db mouse skeletal muscle compared with normal db/+ mice. CpG site 2 also demonstrated significantly increased methylation in db/db mouse skeletal muscle; this is possibly mediated by factors other than miR-539-5p in vivo. To investigate whether Dnmt3b inhibition alone might affect Srebf1 levels, C2C12 cells were transfected with Dnmt3b small interfering RNA (siRNA), and this caused significant inhibition of DNMT3b levels (Figures 4E and 4F) associated with notable increases in Srebf1 transcript levels at 100 nM (Figure 4G). This was confirmed using nanaomycin A, a selective DNMT3b inhibitor. As shown in Figures 5A and 5B, compared with control cells, although nanaomycin A (NA) significantly inhibited DNMT3b levels at 10 μM, there was no significant change in the transcript or protein levels of DNMT1 and DNMT3a at any of the doses used. This change in DNMT3b levels was not evident at 1 or 5 μM. In Hep3B cells, similar patterns of NA-induced decreases in DNMT3b protein levels at higher doses have been shown by Lai et al.28 Interestingly, however, there was a modest but significant decrease in DNMT activity in the presence of 5 μM NA, although this inhibitory effect was more pronounced at 10 μM concentration (Figure 5C). Such NA-induced inhibition of DNMT activity at 5 μM without a change at the transcript or protein level has been shown by Kuck et al.29 This was consequently accompanied by an increase in the transcript levels of Srebf1 at 10 μM but not at 5 μM (Figure 5D), even though there was a modest decrease in DNMT activity at 5 μM. This may possibly be due to the fact that the modest decrease in DNMT activity at 5 μM NA is not sufficient to exert effects on Srebf1 transcription. These results suggest that Dnmt3b is a crucial regulator of Srebf1 and that, by targeting Dnmt3b, miR-539-5p regulates cellular Srebf1 levels. To confirm that the miR-539-5p-Dnmt3b axis is
Figure 4. miR-539-5p regulates Srebf1 transcript levels by inhibiting Dnmt3b expression and altering CpG methylation on the Srebf1 gene in C2C12 cells

(A) Differentiated C2C12 cells were transfected with the Scr or the miR-539-5p mimic with or without its inhibitor. After 48-h incubation, cells were harvested, and expression of transcript levels of Prkab2, Srebf1, and Irs1 (as described under “Materials and methods”) was evaluated using qRT-PCR. 18S rRNA was used as the loading control. (B) Schematic of CpG islands across the Srebf1 gene in mice. Each CpG site was randomly split into three regions, and primers were designed to amplify these regions within each CpG island using primers sets (P1, P2, and P3) as shown. (C) Differentiated C2C12 cells were transfected as in (A) with Scr or the miR-539-5p mimic, and up on termination of incubation, genomic DNA was isolated, sheared, and immunoprecipitated (2 mg) with a 5-methylcytosine antibody (2 mg) or non-immune rabbit IgG (2 mg) and incubated overnight at 4°C. Methylation-enriched CpG regions within the Srebf1 gene were quantified by real-time PCR using CpG region-specific primers. (D) Genomic DNA isolated from skeletal muscle of normal db/+ and diabetic db/db mice was sheared, and the methylation status within Srebf1 was quantified by real-time PCR as described in (C). Differentiated C2C12 cells were transfected with the Scr or Dnmt3b siRNA (50–100 nM), and after 48 h, cells were harvested, and Dnmt3b expression was quantified at the transcript (E) and protein (F) levels. 18S rRNA and HSC70 were used as normalization controls, respectively. (G) Differentiated C2C12 cells transfected with the Scr or Dnmt3b siRNA (50–100 nM) were harvested, and 1 M RNA was reverse transcribed to evaluate the transcript levels of Srebf1 by qRT-PCR. 18S rRNA was used as the normalization control. Values are means ± SEM of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. ns, non-significant.
Figure 5. Dnmt3b inhibition rescues the miR-539-5p inhibitor-induced decrease in Srebf1 levels in C2C12 cells

(A and B) C2C12 cells were incubated in the presence of a Dnmt3b inhibitor (nanaomycin A [NA]) at doses of 1, 5, and 10 μM. Control cells were incubated in the presence of DMSO. After 48 h, Dnmt1, Dnmt3a, and Dnmt3b levels were evaluated by qRT-PCR (A) and western blot (B). 18S rRNA and HSC70, respectively, were used as the loading controls. D, DMSO. (C) Cells incubated as in (A) were assayed for activity of DNMT as described under “Materials and methods.” Data were normalized to the total protein content. (D) Total RNA was isolated from cells incubated as in (A), and the transcript levels of Srebf1 were quantified using specific primers. 18S rRNA was used as the normalization control. (E–G) C2C12 cells were transfected with the Scr or miR-539-5p inhibitor (25–50 nM), and after 48 h, the status of Dnmt3b (E and F) and Srebf1 (G) were evaluated by qRT-PCR and western blot analysis. HSC70 and 18S rRNA were taken as the normalizing controls for western blot and qRT-PCR experiments, respectively. (H and I) C2C12 cells were transfected with the Scr or miRNA-539-5p alone (50 nM) or along with Dnmt3b siRNA (100 nM), and after 48 h, Dnmt3b (H) and Srebf1 (I) transcript levels were evaluated by qRT-PCR. 18S rRNA was taken as the endogenous control. (J) C2C12 cells were transfected with the empty vector or the Dnmt3b overexpression vector (1 μg) together with the Scr or miR-539-5p (50 nM); after 48 h, total RNA was isolated, and the transcript levels of Srebf1 were evaluated by qRT-PCR. 18S rRNA was used as the endogenous control. All experiments were performed at least three times for each group, and values are reported as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

indicates that the effects of miR-539-5p on Srebf1 are mediated through Dnmt3b.

In vivo antagonism of miR-539-5p induces hyperglycemia and impairs oral glucose tolerance in mice

To determine the physiological significance of the miR-539-5p-DNMT3b interaction, mice were injected intravenously (i.v.) with the scramble or the miR-539-5p antagonist at a dose of 5 mg/kg. A schematic of the injection schedule and experimental protocol is shown in Figure 6A. Blood glucose was measured randomly on the next day after every injection, and there was significant increase in blood glucose levels in antagonim-injected mice compared with scramble-injected mice (Figure 6B). After 6 and 12 h of fasting, there was a significant increase in fasting glucose levels in miR-539-5p antagonist-administered mice (Figure 6C) together with increased circulatory insulin levels (Figure 6D). An oral glucose tolerance test (OGTT) demonstrated significant impairment in glucose tolerance in antagonim-injected mice compared with scramble-injected mice (Figure 6E). Compared with scramble-injected mice, serum triglycerides and cholesterol levels were also significantly elevated in miR-539-5p antagonist-injected mice (Figures 6F and 6G). All of these results demonstrate that inhibition of miR-539-5p impairs glucose metabolism and alters serum lipid profiles in mice.

miR-539-5p inhibition in vivo alters Dnmt3b and Srebf1 expression in skeletal muscle of mice

Because, as shown above, administration of the miR-539-5p antagonist induces hyperglycemia, hyperinsulinemia, and hyperlipidemia in mice, we sought to examine Dnmt3b and Srebf1 expression in skeletal muscle of these mice. miR-539-5p antagonist administration to mice significantly increased Dnmt3b levels in skeletal muscle (Figures 7A and 7B) and decreased the transcript levels of Srebf1 (Figure 7C), indicating that, by increasing Dnmt3b levels, miR-539-5p antagonism decreases Srebf1 transcription in skeletal muscle tissue in vivo. However, compared with scramble-injected mice, neither Dnmt3b nor Srebf1 transcript levels were altered in the livers of miR-539-5p antagonist-injected mice (Figures 7D and 7E), indicating
that the effects of miR-539-5p on Dnmt3b and Srebf1 are possibly tissue specific. This was evident because transfection of hepatic Hepa 1-6 cells with the miR-539-5p (50 nM) mimic did not cause any significant change in the transcript levels of Dnmt3b or Srebf1 (Figure 7F).

In vivo administration of miR-539-5p normalizes hyperglycemia, improves oral glucose tolerance, and restores miR-539-6p, Dnmt3b, and Srebf1 levels in skeletal muscle of db/db mice

A schematic of the in vivo protocol is shown in Figure 8A. Random and fasting glucose levels were measured, and after the final injection, an OGTT was performed on Scr- and miR-539-5p-antagomir-injected mice after 12 h of fasting. (C and D) Fasting blood glucose levels at 6 and 12 h of fasting (C) and circulatory insulin levels (D) were measured in Scr- and miR-539-5p-antagomir-injected mice. (E) OGTT was performed on Scr- and miR-539-5p-antagomir-injected mice after 12 h of fasting. (F and G) Serum triglyceride (F) and cholesterol (G) levels were measured in sera of Scr- and miR-539-5p-antagomir-injected mice as described under *Materials and methods.* Data are from at least four animals in each group, and values are means ± SEM. *p < 0.05 compared with Scr-injected mice.

DISCUSSION

In this study, we present data to show that miR-539-5p targets DNMT3b and consequently regulates Srebf1 transcript levels in skeletal muscle during diabetes. Aberrant DNA methylation is linked to several diseases, including cancers, heart diseases, inflammation, skin diseases, etc.30–33 DNA methylation mediated by DNMTs is a covalent modification of DNA and almost exclusively occurs at cytosine residues in CpG islands that are frequently located within the promoter regions and close to transcription start sites. Such modifications determine the spatial and temporal patterns of transcript levels within a cell and signify the importance of DNMT regulation in cellular physiology. The activity and cellular levels of DNMTs are regulated at the level of activation, stabilization, and recruitment at specific sites and heterochromatin regions on the
This may be mediated by transcription factors, piRNA complexes, other noncoding RNAs, and post-translational modifications. Other miRNAs, like miR-126, miR-152, and miR-148, have also been shown to directly target and alter levels of DNMTs. Embryonic stem cells from Dicer-deficient mice have significantly decreased levels of DNMT1, DNMT3a, and DNMT3b. Our current study demonstrates regulation of DNMT3b by miR-539-5p in skeletal muscle during diabetes. DNMT3b and miR-539-5p display inverse patterns of expression in skeletal muscle of db/db and HFD diabetic mice. By binding to the 3’ UTR of Dnmt3b, miR-539-5p significantly decreases the transcript and protein levels of DNMT3b. These data suggest a critical role of miRNAs in mediating post-transcriptional regulation of DNMTs at the onset and during progression of diverse diseased states.

Abnormal DNMT levels trigger aberrant methylation patterns of genes that consequently regulate their expression levels and cell function. Interestingly, DNMT3b, in its dual capacity, controls diverse cellular events. It provides accessory functions by supporting the catalytic activity of other DNMTs, HDACs, etc.; mediates methylation; represses gene expression; and regulates essential pathways.
On the other hand, its intrinsic catalytic function alone at least in part determines its methyltransferase activity, which is evident by hypomethylation of target gene loci in Dnmt3b/C0/C0 and Dnmt3bCI/CI mice (expressing catalytically inactive Dnmt3b) compared with WT mice.39 Generally, hypermethylation of DNA regions close to transcription start sites is associated with suppression of gene expression and vice versa.5 It is believed that the transcriptional decrease because DNA hypermethylation is possibly due to decreased binding of transcription factors to their respective binding sites. Our study shows that miR-539-5p, by inhibiting DNMT3b levels, increases the transcript levels of Srebf1. Srebf1 harbors potential CpG islands at two regions, and the one spanning the transcription start site is hypomethylated in the presence of miR-539-5p, and this elevates Srebf1 transcription. Although our data support the fact that such hypomethylation is due to a miR-539-5p-targeted decrease in DNMT3b levels and, consequently, of its activity, a contribution of its independent methyltransferase catalytic activity alone cannot be ruled out and needs further investigation, especially because, despite being dispensable, the catalytic activity of DNMT3b is critically associated with genomic elements that control tumorigenesis in mice by regulating processes involved in cellular transformation, including that of phosphatidylinositol 3-kinase (PI3K)-Akt, mitogen-activated kinase (MAPK), etc.40

Srebf1 encodes a helix-loop-helix leucine zipper transcription factor, SREBP1, that binds to the sterol regulatory element primarily found

Figure 8. miR-539-5p administration improves hyperglycemia and normalizes miR-539-5p, Dnmt3b, and Srebf1 levels in skeletal muscle of diabetic db/db mice

(A) Schematic of the experimental design for db/+ and db/db animals. db/db mice were injected with the Scr to miR-539-5p mimics (i.v. through the tail vein) at a dose of 5 mg/kg body weight. db/+ mice were injected with Scr. Three injections were given, one every other day. An OGTT was done on day 6, and on day 8, mice were euthanized. (B and C) Random blood glucose levels on the following day after every injection (B) and fasting blood glucose levels at 6 and 12 h of fasting (C) were measured in db/+ and db/db mice. (D) OGTT was performed after an oral glucose dose (2 g/kg body weight), and blood glucose levels were measured at time intervals of 30, 60, 90, and 120 min after the glucose feed. (E and F) Serum triglyceride (E) and cholesterol (F) levels were measured in sera of db/+ and db/db mice. (G–I) Total RNA was isolated from skeletal muscle tissue of db/+ mice injected with the Scr or db/db mice injected with the Scr or miR-539-5p mimics, and the transcript levels of miR-539-5p (G), Dnmt3b (H), and Srebf1 (I) were assessed by qRT-PCR. Sno234 or 18S rRNA was taken as the normalization control. Values are means ± SEM of four animals in each group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with db/+ mice injected with Scr; #p < 0.05, ##p < 0.01 compared with db/db mice injected with Scr.
in genes involved in cholesterol biosynthesis and lipid homeostasis. The encoded protein is located at the endoplasmic reticulum and, upon cleavage, translocates to the nucleus to initiate target gene transcription. The Srebf1 gene is expressed in various tissues, and abnormal levels are linked to several diseases, like diabetes, obesity, NAFLD, Parkinson’s disease, and hepatocellular carcinoma.

With respect to insulin resistance and type 2 diabetes, genetic variability within the Srebf1 gene is suggested to play a significant role. Genome-wide studies in the European population depict a strong link of type 2 diabetes with the Srebf1 locus, and single-nucleotide polymorphisms within this gene have been associated with obesity, insulin resistance, and abnormal lipid levels. Insulin upregulates SREBP1c levels in skeletal muscle, which increases the levels of glycolytic and lipogenic genes. A recent study from our laboratory demonstrated decreased transcript levels of Srebf1 in skeletal muscle of diabetic mice. Srebf1 transcript levels have been shown to be downregulated in skeletal muscle of diabetic subjects, and, interestingly, these diabetic subjects had poor metabolic control and a negative correlation between Srebf1 transcript levels and circulating HbA1c levels.

Our results in the current study show that, by targeting Dnmt3b, miR-539-5p increases Srebf1 transcript levels in skeletal muscle cells. In vivo antagonism of miR-539-5p increases Dnmt3b levels and downregulates the transcript levels of Srebf1. This was accompanied by hyperglycemia, hyperinsulinemia, hypercholesterolemia, and hypertriglyceridemia. Hence, decreased Srebf1 levels as seen in skeletal muscle during diabetes are due to the increased levels and activity of Dnmt3b and the consequent hypermethylation and silencing of Srebf1, all triggered by decreased miR-539-5p levels. Our data show that, within skeletal muscles of db/db mice, there is significant hypermethylation at these regions compared with normal db/+ mice. Similar hypermethylation patterns on the Srebf1 promoter have been reported in the liver and adipose tissue of diabetic subjects. However, in our study, compared with scramble-injected mice, transcript levels of Srebf1 were not altered in the livers of miR-539-5p antagonist-injected mice. This might be due to the fact that miRNAs are known to exert tissue-specific effects, and miR-539-5p probably does not specifically affect the Dnmt-3b-Srebf1 axis in the liver. Our data also demonstrate that in vivo administration of miR-539-5p to diabetic db/db mice normalizes hyperglycemia and improves oral glucose tolerance together with normalization of Dnmt3b and Srebf1 levels in the skeletal muscle.

This study identifies miR-539-5p as a novel regulator of Srebf1 transcription and provides key information for modulating its levels for therapeutic intervention. We provide evidence showing that, in skeletal muscle during diabetes, miR-539-5p levels are downregulated, accompanied by increased Dnmt3b and decreased Srebf1 levels. As in the liver and adipose tissue, Srebf1-encoded SREBP1c in skeletal muscle mediates insulin effects on specific genes, and its regulation of glycolytic and lipogenic genes indicates its relevance in maintaining muscle insulin sensitivity. These events could be important in aberrant skeletal muscle metabolism in pathophysiological states such as obesity and diabetes.

MATERIALS AND METHODS

Animal experiments

Ten- to twelve-week-old male normal mice (C57BLKs lepdb/+; body weight, 23.06 ± 0.47 g; blood glucose, 104.5 ± 2.19 mg/dL) and diabetic mice (C57BLKs lep+db; body weight, 42.04 ± 2.19 g; blood glucose, 390.25 ± 57.85 mg/dL) (n = 4) were obtained from the animal house facility of the CSIR-Central Drug Research Institute (CDRI) (Lucknow, India) and maintained with ad libitum food and water at the animal house facility of the CSIR-Institute of Genomics and Integrative Biology (IGIB) (Delhi, India). Seven-week-old C57BL/6 male mice obtained from the animal house facility of the CSIR-IGIB were fed a chow diet (10% calories from fat) or HFD (60% calories from fat) (Research Diets, NJ, USA) for 6 months; there was an approximately 40% increase in body weight, and glucose levels increased by around 45% in HFD-fed animals compared with chow diet-fed mice. Mice were euthanized, and skeletal muscle was isolated and stored in RNAlater (Ambion, TX, USA) or transferred to −80°C for further experiments. Another set of 10- to 12-week-old male C57BL/6 mice procured from the animal house facility of the CSIR-IGIB were randomly assigned to two groups (n = 5 per group) and maintained at a 12:12 h light:dark cycle with ad libitum food and water. Animals were injected i.v. (three injections, one every other day) with the scramble or miR-539-5p antagonist (Dharmacon, CO, USA) at a dose of 5 mg/kg body weight using in vivo-jetPEI (Polyplus-Transfection, France) according to the manufacturer’s instructions. Blood glucose of mice was measured randomly the next day after every injection. The day after the third injection, animals were fasted overnight for an OGTT. On the eighth day after the first injection, mice were euthanized, and blood samples and skeletal muscle and liver tissue were collected for further experiments. For in vivo injections in normal db/+ mice (C57BLKs; body weight, 24.66 ± 0.76 g; blood glucose, 121.25 ± 11.03 mg/dL) and diabetic db/db mice (C57BLKs; body weight, 46.94 ± 1.52 g; blood glucose, 225.0 ± 19.32 mg/dL) (n = 5), db/db mice were injected with the scramble or miR-539-5p mimics at a dose of 5 mg/kg body weight i.v. via the tail vein using in vivo-jetPEI (three doses, one every other day). db/+ animals were injected with a scramble oligonucleotide. One day after the last injection, animals were fasted overnight, and an OGTT was performed as described below. Animals were then euthanized, and blood and skeletal muscle tissue were collected and stored for metabolic profiling and qRT-PCR as described. In vivo-injected oligonucleotides had 2′O-methyl modifications with phosphorothioate linkages and a cholesterol moiety linked at the 3′ end by a hydroxyprolinol linkage (Sigma, MO, USA). All animal experiments were approved by the Institute Animal Ethical Committee and regulated by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) (New Delhi, India).
DNMT activity assay
DNMT activity in skeletal muscle of normal and diabetic mice or cell lysates was measured using the colorimetric DNMT activity quantification kit (Abcam, UK) according to the manufacturer’s instructions. Briefly, 20 μg of lysate (lysed in RIPA lysis buffer containing protease and phosphatase inhibitor) was incubated with Adomet buffer (containing S-adenosyl methionine) in a universal DNMT substrate-coated microplate, and the methylated DNA (substrate) was quantified using a capture antibody (anti-5-methylcytosine antibody) and a detection antibody. Absorbance was measured in a microplate reader (Tecan, Switzerland) at 450 nm, and DNMT activity was expressed as optical density (OD) per hour per microgram of protein.

Cell culture and treatment
C2C12, mouse myoblast, and mouse Hepa1-6 cells were obtained from the National Centre for Cell Science (NCCS) (Pune, India) and maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (Gibco, Cambridge, UK) and antibiotic/antimycotic solution (Gibco) at 37°C in 5% CO2. At a confluence of 70%–80%, the medium of C2C12 cells was replaced with high-glucose DMEM supplemented with 2% (v/v) horse serum (Gibco), to promote differentiation of myoblasts into myotubes, which were visible within 4 days of incubation. Differentiated cells were transfected with the scramble or mimics of miR-539-5p, miR381-3p, or miR-31-5p (1–50 nM) (Dharmacon). Wherever mentioned, along with the miR-539-5p mimic, the scramble or the miR-539-5p inhibitor (Dharmacon) was co-transfected at a concentration of 50 nM using Lipofectamine RNAiMax (Invitrogen, MA, USA) and OptiMEM (Gibco). After 48 h of incubation, cells were harvested for qRT-PCR and western blotting to evaluate target gene expression. For the miR-539-5p inhibitor studies, C2C12 cells transfected with the scramble or miR-539-5p inhibitor (25–50nM) were harvested after 48 h to evaluate the levels of DNMT3b and Srebf1. For validation in primary cells, human primary myoblast cells (PromoCell, Germany) were cultured in 12-well plates (CellBIND, Corning, NY, USA) in skeletal muscle growth medium (PromoCell) according to the manufacturer’s instructions. Upon attaining 80% confluence, cells were transfected as above and harvested for further use. For Dnmt3b siRNA treatment, differentiated C2C12 cells were transfected with the scramble or Dnmt3b siRNA (50–100 nM) (Sigma) using Lipofectamine RNAiMax (Invitrogen) and OptiMEM (Gibco); upon termination of incubation at 48 h, cells were harvested for qRT-PCR and western blotting as described below. To confirm the effects of DNMT3b inhibition, differentiated C2C12 cells were incubated in the presence of DMSO or the DNMT3b inhibitor NA (Calbiochem, MA, USA) at a dose of 1, 5, and 10 μM as described by Lai et al.28 After 48 h, cells were harvested, lysed, and processed as described above to evaluate Dnmt1, Dnmt3a, Dnmt3b, and Srebf1 levels. Whether DNMT3b mediates the effects of miR-539-5p on Srebf1 was studied by co-transfecting C2C12 cells with the miR-539-5p inhibitor (50 nM) with the scramble or Dnmt3b siRNA (100 nM), and after 48 h, Dnmt3b and Srebf1 transcript levels were evaluated by qRT-PCR as described below. To explore the effect of overexpression of miR-539-5p in the liver, mouse hepatic Hepa 1-6 cells were transfected with the scramble or miR-539-5p mimic (50 nM). After 48 h of incubation, cells were harvested to evaluate the expression of miR-539-5p, Dnmt3b, and Srebf1.

RNA isolation and qRT-PCR
RNA from cells and tissues was isolated using TRIzol according to the manufacturer’s protocol and quantified using a plate reader (Infinite 200 Pro, Tecan, Switzerland) with 260/280 ratios between 1.9 and 2.0. 1 μg of RNA was used for cDNA synthesis using RevertAid reverse transcriptase (Thermo Fisher Scientific, USA) and random hexamers (Thermo Fisher Scientific, MA, USA). Quantitative PCR was performed to evaluate gene and miRNA expression in a StepOne Plus real-time PCR machine (Applied Biosystems, MA, USA) using SYBR Green Master Mix (Applied Biosystems, USA) and primers as in Table S1. 18S rRNA and Sno234 were used as normalization controls for genes and miRNA expression, respectively. Relative gene expression was calculated by the ∆Ct method.35

Western blotting
Protein samples were isolated from cells and tissues using RIPA lysis buffer (Sigma) containing phosphatase (Calbiochem, Germany) and protease inhibitors (Calbiochem, Germany). 40 μg of protein was run on SDS-PAGE and subjected to western blot analysis using DNMT1 (Cell Signaling Technology, MA, USA; 1:2,000 dilution), DNMT3a (Cell Signaling Technology, MA, USA; 1:2,000 dilution), and DNMT3b (Abcam, UK; 1:2,000 dilution) antibodies. Immunoreactive bands were detected using horseradish peroxidase (HRP)-linked secondary antibodies (Genet, India), followed by detection with femtolUCELNT HRP-Plus reagent (G-Bioscience, MO, USA). HSC70 was used as the loading control for normalization. Densitometric analyses for western blots were performed using AlphaEase FC imaging analysis software (Alpha Innotech, CA, USA), and the intensity of each band was normalized to background intensity.

Cloning, mutagenesis, and luciferase assay
Luciferase reporter constructs containing the 3’ UTR of Dnmt3b harboring the binding site for miR-539-5p were generated in a psiCheck2 vector (Promega, WI, USA) using primers as in Table S1. Substitution mutation was done in the binding site of miR-539-5p using the XL site-directed mutagenesis kit (Agilent Technologies, Canada) and mutation-specific primers (Table S1). Differentiated C2C12 cells were co-transfected with the WT (100 ng) or the MT 3’ UTR reporter plasmid (100 ng) along with the scramble or the miR-539-5p mimic (50 nM) with or without the miR-539-5p inhibitor (50 nM). A dual luciferase assay (Promega, USA) was performed after 48 h of incubation, and luminescence was measured in a multimode reader (Infinite M200 Pro, Tecan, Switzerland). Renilla luciferase values were normalized to those of firefly luciferase. As described by Phatak and Donahue,56 to validate the binding of miR-539-5p with the 3’ UTR of Dnmt3b mRNA, C2C12 cells were transfected with biotin-labeled scramble or biotin-labeled miR-539-5p mimic (50 nM) (QIAGEN, USA). After 48 h of incubation, cells were harvested, lysed, and incubated overnight with Dynabead-linked...
Streptavidin C1 (Thermo Fisher Scientific, USA) at 4°C. Dynabeads were pulled down on a magnetic stand, and the bound RNA was isolated by using TRIzol. Enrichment of Dnmt3b mRNA with biotin-labeled miR-539-5p mimic was quantified by real-time PCR using Dnmt3b-specific primers and compared with that of scramble-transfected cells.

The complete coding sequence of mouse Dnmt3b was cloned into a pcDNA3.1(+) vector (Thermo Fisher Scientific, USA) using specific primers (Table S1). Differentiated C2C12 cells were transfected with the empty vector or the Dnmt3b overexpression vector (0.5–1 µg) alone or with the miR-539-5p mimic (50 nM) using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s protocol. After 48 h, cells were lysed, total RNA was isolated, and the transcript levels of Srebf1 were assessed by qRT-PCR as described above.

Bioinformatics analysis
miRNA target prediction was performed using three online public databases: TargetScan (http://www.targetscan.org/vert_72/), mirDB (http://mirdb.org/mirdb/index.html), and miRanda (http://microrna.org/). The presence of CpG islands within the genes was analyzed using the UCSC Genome Browser (https://genome.ucsc.edu/).

MeDIP
Differentiated C2C12 cells were transfected with scramble (50 nM) or miR-539-5p mimic (50 nM) for 48 h. Upon termination of incubation, genomic DNA was isolated from these cells and from skeletal muscle of db/db and db/db animals using phenol/chloroform/isoamyl alcohol. Isolated genomic DNA was randomly sheared into 200–700-bp fragments with six sets of sonication cycles (15-s pulse and 30-s incubation between each pulse) using an ultrasonic homogenizer (Takashi, Japan). Sonicated genomic DNA was quantified in a plate reader (Infinite 200 Pro, TECAN, Switzerland); 2 µg of sonicated genomic DNA was used for immunoprecipitation with 5-methylcytosine antibody (2 µg) (Epigentek, USA) or non-immune rabbit immunoglobulin G (IgG) (Epigentek, USA) and incubated overnight at 4°C. Methylated CpG regions within the Srebf1 gene were quantified by real-time PCR using CpG region-specific primers (primers against each CpG island split into regions of 150–180 bp; Table S1).

OGTT
Scramble- and miR-539-5p antagonim-injected mice or db/+ and db/db mice were fasted for 12 h for an OGTT. Fasting blood glucose was measured prior to an oral glucose dose (2 g/kg body weight) for the OGTT. Blood glucose levels were measured at time intervals of 30, 60, 90, and 120 min after the oral glucose feed.

Blood and tissue collection
Blood glucose was measured using the OneTouch Select glucometer (Life Scan Europe, Switzerland). For insulin, cholesterol, and triglyceride analysis, blood samples were collected from mice during euthanization, centrifuged at 1,300 × g for 10 min at 4°C to collect serum, and stored at −20°C for further use. Insulin levels were measured using the insulin ELISA kit (G-Biosciences, USA) according to the manufacturer’s protocol. Serum triglycerides, cholesterol, and cholesteryl ester levels were measured using the respective kits following the manufacturer’s instructions (BioVision, CA, USA). Skeletal muscle was isolated from all groups of mice and stored in RNAlater (Ambion, USA) at −80°C or directly transferred to −80°C for protein analysis.

Statistical analysis
All experiments were performed at least three times, and data are represented as means ± SEM. Student’s t test and one-way ANOVA were performed for statistical significance; p < 0.05 was considered statistically significant.

Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtn.2022.08.013.

ACKNOWLEDGMENTS
We thank Mayank Garg and Rukshar Khan for help with the experiments and Dr. Shagun Poddar for help with standardizing cell culture experiments. This work was supported by funding from the Council of Scientific & Industrial Research (CSIR), New Delhi, India (BSC0122 and MLP2013). D.K., A.K., and A.R. acknowledge the Council of Scientific and Industrial Research for their fellowships.

AUTHOR CONTRIBUTIONS
M.D. conceived and designed the experiments. D.K. performed most of the experiments. A.K. performed the cloning experiments. This work was supported by funding from the Council of Scientific & Industrial Research (CSIR), New Delhi, India (BSC0122 and MLP2013). D.K., A.K., and A.R. acknowledge the Council of Scientific and Industrial Research for their fellowships.

DECLARATION OF INTEREST
The authors declare no competing interests.

REFERENCES
1. Cole, J.B., and Florez, J.C. (2020). Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol. 16, 377–390.
2. Murea, M., Ma, L., and Freedman, B.I. (2012). Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev. Diabet. Stud. 9, 6–22.
3. Ling, C., and Groop, L. (2009). Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58, 2718–2725.
4. Zhao, J., Goldberg, J., Bremner, J.D., and Vaccarino, V. (2012). Global DNA methylation is associated with insulin resistance. Diabetes 61, 542–546.
5. Moore, I.D., Le, T., and Fan, G. (2013). DNA methylation and its basic function. Neuropsychopharmacology 38(1), 23–38.
6. Barré, R., Yan, J., Egan, B., Treebak, J.T., Rasmussen, M., Fritz, T., Casadahl, K., Krook, A., O’Gorman, D.I., and Zierath, J.R. (2012). Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab. 15, 405–411.
1. Barres, R., Kirchner, H., Rasmussen, M., Yan, J., Kantor, F.R., Krook, A., Näslund, E., and Zierath, J.R. (2013). Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep. 3, 1020–1027.

2. Jinawath, A., Miyake, S., Tanigawa, Y., Akiyama, Y., and Yuasa, Y. (2005). Transcriptional regulation of the human DNA methyltransferase 3A and 3B genes by Sp3 and Sp1 zinc finger proteins. Biochem. J. 385, 557–564.

3. Peterson, E.J., Bogler, O., and Taylor, S.M. (2003). p53-Mediated repression of DNA methylation between an adjacent lysine and serine determines human DNMT1 stability. Nat. Genet. 31, 1305–1315.

4. Ligthart, S., Marzi, C., Aslibekyan, S., Mendelson, M.M., Conneely, K.N., Tanaka, T., et al. (2016). DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. Genome Biol. 17, 256–269.

5. Aravin, A.A., Sachidanandam, R., Bourc, D., Schaefer, C., Perez, D., Toth, K.F., Bestor, T., and Hannon, G.J. (2008). A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol. Cell 31, 785–799.

6. Denis, H., Ndlou, M.N., and Fuks, F. (2011). Regulation of mammalian DNA methylation: a route to new mechanisms. EMBO Rep. 12, 647–656.

7. Shimokon, L., Hugenschmidt, T., Berninger, P., Gaidatzis, D., Mohr, F., Artus-Revel, C.G., Zavolan, M., Svoboda, P., and Filipowicz, W. (2008). MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mammalian stem cells. Nat. Struct. Mol. Biol. 15, 259–267.

8. Benetti, R., Gonzalo, S., Jiao, I., Muñoz, P., Gonzalez, S., Schneeft, S., Murchison, E., Andl, T., Chen, T., Klatt, P., et al. (2008). A mammalian microRNA cluster controls DNA methylation and telomere maintenance by Rbhl2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol. 15, 998–1005.

9. Nowialis, P., Lopusna, K., Opavska, J., Haney, S.L., Abraham, A., Sheng, P., et al. (2020). Catalytically inactive Dnmt3b rescues mouse embryonic development by accessory and repressive functions. Nat. Commun. 10, 4374–4389.

10. Lopes de Silanes, I., Gorospe, M., Taniguchi, H., Abdelmohsen, K., Srikantan, S., Estève, P.O., Chang, Y., Samaranayake, M., Upadhyay, A.K., Horton, J.R., Feehery, G.R., Cheng, X., and Pradhan, S. (2010). A methylation and phosphorylation switch targets human DNMT3b protein coding region. RNA 16, 872–877.

11. Barbé, R., Osler, M.E., Yan, J., Rune, A., Fritz, T., Caidahl, K., Krook, A., and Zierath, J.R. (2009). Non-CpG methylation of the PGC-1α promoter through DNMT3B controls mitochondrial density. Cell Metab. 10, 189–198.

12. Jacobsen, S.C., Brons, C., Bork-Jensen, J., Ribe-Madsen, R., Yang, B., Lara, E., Hall, E., Calvanese, V., Nilsson, E., Jørgensen, S.W., et al. (2012). Effects of short-term high-fat feeding on genome-wide DNA methylation in the skeletal muscle of healthy young men. Diabetologia 55, 3341–3349.

13. Nietert, M.D., Dayeh, T., Volkov, P., Elgøri, T., Hall, E., Nilsson, E., Yang, B.T., Lang, P., Parikh, H., Wessman, Y., and et al. (2012). Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes 61, 3322–3332.

14. Bibeł-Madsen, R., Fraga, M.F., Jacobsen, S., Bork-Jensen, J., Lara, E., Calvanese, V., Fernandez, A.F., Friedrichsen, M., Vind, B.F., Hojlund, K., et al. (2012). Genome-wide analysis of DNA methylation differences in muscle and fat from monzygotic twins discordant for type 2 diabetes. PLoS One 7, e51302.

15. Agarwal, P., Sirivastava, R., Srivastava, A.K., Ali, S., and Datta, M. (2013). miR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochim. Biophys. Acta 1832, 1294–1303.

16. Kesharwani, D., Kumar, A., Poojary, M., Scaria, V., and Datta, M. (2021). RNA sequencing reveals potential interacting networks between the altered transcriptome and miRNA network in the skeletal muscle of diabetic mice. Biosci. Rep. 41, 20210495.

17. Lai, S.C., Su, Y.T., Chu, C.C., Kuo, Y.C., Lee, K.F., Wu, Y.C., et al. (2019). DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J. Exp. Clin. Cancer Res. 38, 474–491.

18. Kuck, D., Caulifeld, T., Lyko, F., and Medina-Franco, J.L. (2010). Nanaoymycin A sensitively inhibits Dnmt3b and rescues silenced tumor suppressor genes in human cancer cells. Mol. Cancer Ther. 9, 3015–3023.

19. Zhang, P., Zhao, M., Liang, G., Yin, G., Huang, D., Su, F., Zhai, H., Wang, L., Su, Y., and Lu, Q. (2013). Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J. Autoimmun. 41, 17–24.

20. Braconi, C., Huang, N., and Patel, T. (2010). MicroRNA-dependent regulation of drug response and therapeutic targeting. Mol. Cancer 9, 32–42.

21. Peterson, E.J., Bögler, O., and Taylor, S.M. (2003). p53-Mediated repression of DNA methylation between an adjacent lysine and serine determines human DNMT1 stability. Nat. Genet. 31, 125–129.

22. Estève, P.O., Chang, Y., Samaranayake, M., Upadhyay, A.K., Horton, J.R., Feehery, G.R., Cheng, X., and Pradhan, S. (2010). A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability. Nat. Struct. Mol. Biol. 18, 42–48.

23. Goyal, R., Rathert, P., Lother, H., Gowher, H., and Jeltsch, A. (2007). Phosphorylation of serine-515 activates the mammalian maintenance methyltransferase Dnmt1. Epigenetics 2, 155–160.

24. López de Silanes, I., Gorospe, M., Taniguchi, H., Abdelmohsen, K., Srikantan, S., Alaminos, M., Berdaso, M., Erdingiu, R.G., Fraga, M.F., Jacinto, F.V., and Esteller, M. (2009). The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA. Nucleic Acids Res. 37, 2658–2671.

25. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., et al. (2007). MicroRNA-29 family reverses aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 104, 15805–15810.

26. Agarwal, P., Srivastava, R., Srivastava, A.K., Ali, S., and Datta, M. (2013). miR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochim. Biophys. Acta 1832, 1294–1303.

27. Bibeł-Madsen, R., Fraga, M.F., Jacobsen, S., Bork-Jensen, J., Lara, E., Calvanese, V., Fernandez, A.F., Friedrichsen, M., Vind, B.F., Hojlund, K., et al. (2012). Genome-wide analysis of DNA methylation differences in muscle and fat from monzygotic twins discordant for type 2 diabetes. PLoS One 7, e51302.
45. Ivatt, R.M., and Whitworth, A.J. (2014). SREBF1 links lipogenesis to mitophagy and sporadic Parkinson disease. Autophagy 10, 1476–1477.

46. Eberlé, D., Clément, K., Meyre, D., Sabatou, M., Vaxillaire, M., Le Gall, A., Ferré, P., Basdevant, A., Frouel, P., and Foufelle, F. (2004). SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 53, 2153–2157.

47. Demenais, F., Kanninen, T., Lindgren, C.M., Wiltshire, S., Gaget, S., Dandrieux, C., Almgren, P., Sjögren, M., Hattersley, A., Dina, C., et al. (2003). A meta-analysis of four European genome screens (GIFT Consortium) shows evidence for a novel region on chromosome 17p11.2–q22 linked to type 2 diabetes. Hum. Mol. Genet. 12, 1865–1873.

48. Laudes, M., Barroso, I., Luan, J., Soos, M.A., You, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A.J., Wareham, N.J., and O‘Rahilly, S. (2004). Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 53, 842–846.

49. Grarup, N., Stender-Petersen, K.L., Andersson, E.A., Jørgensen, T., Borch-Johnsen, K., Sandbaek, A., Lauritzen, T., Schmitz, O., Hansen, T., and Pedersen, O. (2008). Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance. Diabetes 57, 1136–1142.

50. Ide, T., Shimano, H., Yahagi, N., Matsuoka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H., et al. (2004). SREBP1s suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351–357.

51. Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBP-s: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131.

52. Guillet-Denieu, J., Mirulet, V., Le Lay, S., Achouri, Y., Carré, D., Girard, J., Foufelle, F., and Ferré, P. (2002). Sterol regulatory element binding protein-1c expression and action in rat muscles: insulin-like effects on the control of glycolytic and lipogenic enzymes and UCP3 gene expression. Diabetes 51, 1722–1728.

53. Sewter, C., Berger, D., Considine, R.V., Medina, G., Rochford, J., Ciaraldi, T., Henry, R., Dohm, L., Flier, J.S., O‘Rahilly, S., and Vidal-Puig, A.J. (2002). Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-α. Diabetes 51, 1035–1041.

54. Krause, C., Sievert, H., Geißler, C., Grohs, M., El Gammal, A.T., Wolter, S., Ohlert, O., Körp, F., Krämer, U.M., Kasten, M., et al. (2019). Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification. Epigenomics 11, 885–897.

55. Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45.

56. Phatak, P., and Donahue, J.M. (2017). Biotinylated micro-RNA pull down assay for identifying miRNA targets. Bio. Protoc. 7, e2253.